DK2056865T3 - Hidtil ukendt lægemiddelmål til forebyggelse og behandling af tandkødssygdom, forbedring af heling af sår i tandkødet og fremme af tand- og mundsundhed - Google Patents
Hidtil ukendt lægemiddelmål til forebyggelse og behandling af tandkødssygdom, forbedring af heling af sår i tandkødet og fremme af tand- og mundsundhed Download PDFInfo
- Publication number
- DK2056865T3 DK2056865T3 DK07794196.1T DK07794196T DK2056865T3 DK 2056865 T3 DK2056865 T3 DK 2056865T3 DK 07794196 T DK07794196 T DK 07794196T DK 2056865 T3 DK2056865 T3 DK 2056865T3
- Authority
- DK
- Denmark
- Prior art keywords
- plasminogen
- tissue
- mice
- use according
- periodontal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Claims (15)
1. Anvendelse af en forbindelse valgt blandt en naturligt forekommende genetisk variant af plasminogen, Lys-plasminogen, Glu-plasminogen, mini-plasminogen og varianter af plasminogen, som omfatter et eller flere af kringledomænerne og det proteolytiske domæne, til fremstilling afen farmaceutisk sammensætning, som omfatter en effektiv mængde af forbindelsen og eventuelt en farmaceutisk acceptabel bærer, til profylakse, forebyggelse og/eller behandling af infektiøs tandkødssygdom forårsaget af bakteriel, viral eller fungal infektion hos et individ med behov for en sådan behandling.
2. Anvendelse af en forbindelse valgt blandt en naturligt forekommende genetisk variant af plasminogen, Lys-plasminogen, Glu-plasminogen, mini-plasminogen og varianter af plasminogen, som omfatter et eller flere af kringledomænerne og det proteolytiske domæne, til fremstilling af en farmaceutisk sammensætning, som omfatter en effektiv mængde af forbindelsen og eventuelt en farmaceutisk acceptabel bærer, til fremme af heling af infektiøse sår i tandkødet hos et individ med behov for en sådan behandling.
3. Anvendelse ifølge krav 1, hvor tandkødssygdommen er, eller er forårsaget af, en bakteriel infektion.
4. Anvendelse ifølge krav 1, hvor tandkødssygdommen er valgt blandt: periodontitis, gingivitis, nekrotiserende gingivitis, periimplantitis og peri-implantær mucositis.
5. Anvendelse ifølge krav 1, som endvidere aktiverer inflammatoriske celler, forøger keratinocytmigration, reducerer bakterievækst, tjerner nekrotisk væv, forbedrer vævsremodellering og reducerer og/eller forøger cytokinekspressioner.
6. Anvendelse ifølge krav 2, hvor det infektiøse sår i tandkødet er et sår forårsaget af skade eller et sår forårsaget af tandkødskirurgi eller -plastikkirurgi.
7. Anvendelse ifølge krav 2, som endvidere reducerer fibrinaflejring, fremmer keratinocytmigration, forøger cytokinekspressioner, fjerner nekrotisk væv, aktiverer inflammatoriske celler og/eller forbedrer vævsremodellering.
8. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor individet er et menneske, og forbindelsen er humant plasminogen.
9. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor individet er et ikke-humant pattedyr.
10. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor sammensætningen skal administreres ved hjælp afen spray eller ved topikal, oral, lokal eller systemisk administration.
11. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor sammensætningen er valgt fra gruppen bestående af en vandig opløsning, en opløsning til gurgling, en gel, en lotion, en balsam, et pulver, en pasta, en tandpasta, en bandage eller en sårforbinding.
12. Anvendelse ifølge krav 10, hvor sammensætningen til topikal administration omfatter fra 1 pg til 500 mg plasminogen pr. kvadratcentimeter af påføringsområdet.
13. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor administrationen skal gentages mindst én gang.
14. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor administrationen skal gentages dagligt.
15. Farmaceutisk sammensætning til anvendelse ved profylakse, forebyggelse og/eller behandling af infektiøs tandkødssygdom forårsaget af bakteriel, viral eller fungal infektion, hvilken sammensætning omfatter en forbindelse valgt blandt en naturligt forekommende genetisk variant af plasminogen, Lys-plasminogen, Glu-plasminogen, mini-plasminogen og varianter af plasminogen, som omfatter et eller flere af kringledomænerne og det proteolytiske domæne.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82366506P | 2006-08-28 | 2006-08-28 | |
| US94411107P | 2007-06-15 | 2007-06-15 | |
| PCT/SE2007/050586 WO2008027000A2 (en) | 2006-08-28 | 2007-08-28 | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2056865T3 true DK2056865T3 (da) | 2014-03-24 |
Family
ID=39136398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07794196.1T DK2056865T3 (da) | 2006-08-28 | 2007-08-28 | Hidtil ukendt lægemiddelmål til forebyggelse og behandling af tandkødssygdom, forbedring af heling af sår i tandkødet og fremme af tand- og mundsundhed |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20100028321A1 (da) |
| EP (1) | EP2056865B1 (da) |
| JP (1) | JP5566106B2 (da) |
| AU (1) | AU2007290882B2 (da) |
| CA (1) | CA2662083C (da) |
| DK (1) | DK2056865T3 (da) |
| ES (1) | ES2453496T3 (da) |
| HK (1) | HK1134788A1 (da) |
| WO (1) | WO2008027000A2 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2056864T3 (da) | 2006-08-28 | 2014-03-10 | Omnio Healer Ab | Kandidater mod infektion |
| US20130164228A1 (en) * | 2011-12-21 | 2013-06-27 | Colgate-Palmolive Company | Compositions comprising gallates and gallamides |
| US9723558B2 (en) | 2012-04-27 | 2017-08-01 | Qualcomm Incorporated | Method and apparatus for signaling in dense network operations |
| CN104721621A (zh) * | 2015-03-24 | 2015-06-24 | 孟勇 | 一种治疗种植体周围炎的药物组合物及其应用 |
| JP2018524067A (ja) * | 2015-06-11 | 2018-08-30 | アットウィル メディカル ソルーションズ インコーポレイテッド | アンチトロンビン−ヘパリン組成物を利用する医療機器、システムおよび方法 |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| WO2017101872A1 (zh) * | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防和治疗宫颈糜烂的方法 |
| CA3008186A1 (en) | 2015-12-18 | 2017-06-22 | Talengen International Limited | Novel method for preventing and treating angiocardiopathy |
| CN110167583A (zh) | 2016-12-15 | 2019-08-23 | 泰伦基国际有限公司 | 一种治疗冠状动脉粥样硬化及其并发症的方法 |
| WO2018108161A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| WO2018107707A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种改善心脏病变的方法 |
| TWI746581B (zh) * | 2016-12-15 | 2021-11-21 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途 |
| TW201904990A (zh) | 2017-06-23 | 2019-02-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| EP4094775A4 (en) * | 2020-02-06 | 2023-04-19 | Talengen International Limited | METHOD AND MEDICATION FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3023143A (en) | 1959-10-14 | 1962-02-27 | American Cyanamid Co | Process for preparing a veterinary composition |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| US5792835A (en) * | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
| US5397578A (en) | 1994-03-29 | 1995-03-14 | Tovarischestvo S Ogranichennoi Otvetstvennostiju "Taurus" | Method of treatment of chronic purulent inflammations of ear in children |
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| WO2000004941A1 (en) | 1998-07-24 | 2000-02-03 | Pharmacal Biotechnologies, Inc. | Osseous tissue reconstruction system and method |
| AU3862900A (en) * | 1999-03-01 | 2000-09-21 | Uab Research Foundation | Porous tissue scaffolding materials and uses thereof |
| US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| AU2002365408B2 (en) * | 2001-11-26 | 2008-04-24 | Genentech, Inc. | Catheter composition and uses thereof |
| MXPA04007585A (es) | 2002-02-06 | 2005-09-20 | N Zyme Biotec Gmbh | Metodo para la produccion de proteinas recombinantes en microorganismos. |
| CN1420126A (zh) | 2002-07-10 | 2003-05-28 | 牛勃 | 一种重组人纤溶酶原Kringle5突变体蛋白rhPK－5的制备方法 |
| DK2056864T3 (da) | 2006-08-28 | 2014-03-10 | Omnio Healer Ab | Kandidater mod infektion |
-
2007
- 2007-08-28 CA CA2662083A patent/CA2662083C/en not_active Expired - Fee Related
- 2007-08-28 WO PCT/SE2007/050586 patent/WO2008027000A2/en active Application Filing
- 2007-08-28 US US12/439,516 patent/US20100028321A1/en not_active Abandoned
- 2007-08-28 JP JP2009526573A patent/JP5566106B2/ja not_active Expired - Fee Related
- 2007-08-28 AU AU2007290882A patent/AU2007290882B2/en not_active Ceased
- 2007-08-28 DK DK07794196.1T patent/DK2056865T3/da active
- 2007-08-28 EP EP07794196.1A patent/EP2056865B1/en active Active
- 2007-08-28 ES ES07794196.1T patent/ES2453496T3/es active Active
-
2010
- 2010-03-23 HK HK10102997.7A patent/HK1134788A1/xx unknown
-
2015
- 2015-10-23 US US14/921,758 patent/US10086052B2/en active Active
-
2018
- 2018-08-28 US US16/114,940 patent/US20180360931A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2056865B1 (en) | 2013-12-25 |
| US20100028321A1 (en) | 2010-02-04 |
| WO2008027000A2 (en) | 2008-03-06 |
| HK1134788A1 (en) | 2010-05-14 |
| WO2008027000A3 (en) | 2008-05-22 |
| AU2007290882B2 (en) | 2013-02-21 |
| US20180360931A1 (en) | 2018-12-20 |
| US20160184411A1 (en) | 2016-06-30 |
| EP2056865A4 (en) | 2012-01-25 |
| US10086052B2 (en) | 2018-10-02 |
| EP2056865A2 (en) | 2009-05-13 |
| JP2010502601A (ja) | 2010-01-28 |
| AU2007290882A1 (en) | 2008-03-06 |
| JP5566106B2 (ja) | 2014-08-06 |
| CA2662083A1 (en) | 2008-03-06 |
| CA2662083C (en) | 2016-09-20 |
| ES2453496T3 (es) | 2014-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10086052B2 (en) | Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health | |
| CN101563100B (zh) | 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标 | |
| RU2241489C2 (ru) | Композиции матриксных протеинов для залечивания ран | |
| JP5024866B2 (ja) | 創傷治癒のためのマトリックスタンパク質組成物 | |
| Aboyoussef et al. | Detection of Prostaglandin E 2 and Matrix Metalloproteinases in Implant Crevicular Fluid. | |
| JP2007291115A6 (ja) | 創傷治癒のためのマトリックスタンパク質組成物 | |
| Islam et al. | Direct pulp capping procedures–Evidence and practice | |
| EP3413881B1 (en) | Compositions and methods for treating chronic wounds | |
| Ingman et al. | Collagenase, gelatinase and elastase activities in sulcular fluid of osseointegrated implants and natural teeth | |
| Wehner et al. | Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues–From the perspective of dental specialties | |
| Hendiani et al. | Effectiveness of Mangosteen (Garcinia Mangostana L.) Peel Gel on the MMP-8 Levels in Chronic Periodontitis Patients after Scaling and Root Planing | |
| Zarandi et al. | Efect of Anaheal (Bromelain) drug on the Periodontal Clinical Indices in Nonsurgical Periodontal treatment of patients with chronic Periodontitis | |
| Deppe et al. | Content of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in oral mucosa and inflamed periodontal tissue. | |
| Aslam | Double blind study on the efficacy of local application of haemocoagulase solution in wound healing | |
| Kondo et al. | Increased expression of angiopoietin‐like protein 4 regulates matrix metalloproteinase‐13 expression in Porphyromonas gingivalis lipopolysaccharides‐stimulated gingival fibroblasts and ligature‐induced experimental periodontitis | |
| BEKLEN | AN ALTERNATIVE THERAPHY FROM GREEN TEA IN PERIODONTAL | |
| Wahlgren | Matrix metalloproteinases in pulpitis, chronic apical periodontitis and odontogenic jaw cysts | |
| Oberbaum et al. | Inhibition of matrix metalloproteinase activity by a transmucosal patch containing botanical compounds | |
| Boushell | Distribution of matrixmetalloproteinase-2 in human coronal dentin | |
| Long | Characterization of Cellular Response to a Novel Steady State Release of Hydrogen Peroxide at a Concentration Capable of Eradicating | |
| Gaurav | Collagen Membrane Degradation delayed by Tetracycline and Its Semi-Synthetic Analogue Doxycycline-An In Vitro Study. | |
| Delima | Pre-Wounding and Free Gingival Grafts: A Pilot Investigation | |
| Ryan et al. | Tetracyclines in Biology, Chemistry and Medicine 237 ed. by M. Nelson, W. Hillen and RA Greenwald© 2001 Birkhäuser Verlag/Switzerland |